Table 3 Rates of axillary surgery in patients with cT1, cN0, hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer until and after August 2016
< 70 years | ≥ 70 years | |||
|---|---|---|---|---|
Until August 2016 (n = 64) | As of August 2016 (n = 97) | Until August 2016 (n = 24) | As of August 2016 (n = 55) | |
Sentinel lymph node biopsy (n total = 213) | 89.1% | 89.7% | 75.0% | 92.7% |
No axillary surgery (n total = 12) | 4.7% | 4.1% | 8.3% | 5.5% |
Tailored axillary surgerya (n total = 5) | 3.1% | 3.1% | 0.0% | 0.0% |
Axillary lymph node dissection (n total = 10) | 3.1% | 3.1% | 16.7% | 1.8% |